Preliminary findings: Behavioral worsening on donepezil in patients with frontotemporal dementia

被引：171

作者：

Mendez, Mario F. ^{[1
]}

Shapira, Jill S. ^{[1
]}

McMurtray, Aaron ^{[1
]}

Licht, Eliot ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA

来源：

AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY | 2007年 / 15卷 / 01期

关键词：

frontotemporal dementia; donepezil; acetylcholinesterase inhibitors; NEUROPSYCHIATRIC SYMPTOMS; ALZHEIMER-DISEASE; EFFICACY; INHIBITORS; FEATURES;

D O I：

10.1097/01.JGP.0000231744.69631.33

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Objective: The objective of this study was to evaluate donepezil, an acetylcholinesterase inhibitor, in the treatment of frontotemporal dementia (FTD). Methods: Twelve patients with FTD who received donepezil for six months were compared with 12 FTD controls on behavioral measures. Results: The groups did not differ on most variables at baseline or at six months; however, the donepezil group had greater worsening on the FTD Inventory. Four treated patients had increased disinhibited or compulsive acts, which abated with discontinuation of the medication. Conclusion: There were no changes in global cognitive performance or dementia severity; however, a subgroup of patients with FTD can experience worsening of symptoms with donepezil.

引用

页码：84 / 87

页数：4

共 10 条

[1]

CHOW TW, 2002, AM J ALZHEIMERS DIS, V7, P267

[2] Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease [J].

Cummings, JL ;

Schneider, L ;

Tariot, PN ;

Kershaw, PR ;

Yuan, WY .

AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (03) :532-538

[3] The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease [J].

Holmes, C ;

Wilkinson, D ;

Dean, C ;

Vethanayagam, S ;

Olivieri, S ;

Langley, A ;

Pandita-Gunawardena, ND ;

Hogg, F ;

Clare, C ;

Damms, J .

NEUROLOGY, 2004, 63 (02) :214-219

[4] Efficacy of acetylcholinesterase inhibitors in frontotemporal dementia [J].

Lampl, Y ;

Sadeh, M ;

Lorberboym, M .

ANNALS OF PHARMACOTHERAPY, 2004, 38 (11) :1967-1968

[5] Variations in regional SPECT hypoperfusion and clinical features in frontotemporal dementia [J].

McMurtray, AM ;

Chen, AK ;

Shapira, JS ;

Chow, TW ;

Mishkin, F ;

Miller, BL ;

Mendez, MF .

NEUROLOGY, 2006, 66 (04) :517-522

[6]

MILLER BL, 2001, 53 ANN M AM AC NEUR

[7] Rivastigmine in frontotemporal dementia - An open-label study [J].

Moretti, R ;

Torre, P ;

Antonello, RM ;

Cattaruzza, T ;

Cazzato, G ;

Bava, A .

DRUGS & AGING, 2004, 21 (14) :931-937

[8] Frontotemporal lobar degeneration - A consensus on clinical diagnostic criteria [J].

Neary, D ;

Snowden, JS ;

Gustafson, L ;

Passant, U ;

Stuss, D ;

Black, S ;

Freedman, M ;

Kertesz, A ;

Robert, PH ;

Albert, M ;

Boone, K ;

Miller, BL ;

Cummings, J ;

Benson, DF .

NEUROLOGY, 1998, 51 (06) :1546-1554

[9] Neurochemical features of frontotemporal dementia [J].

Procter, AW ;

Qurne, M ;

Francis, PT .

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 1999, 10 :80-84

[10] Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease - A meta-analysis [J].

Trinh, NH ;

Hoblyn, J ;

Mohanty, SU ;

Yaffe, K .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (02) :210-216

← 1 →